Research in context
Evidence before this study
We searched PubMed for all articles published from database inception to Jan 20, 2020, without language restrictions, using the keywords “tau”, “phosphorylated tau”, “CSF tau”, “CSF biomarker”, “Alzheimer's disease”, “plasma tau”, “amyloid”, “MRI”, “PET”, “cognitive decline”, and “hippocampal atrophy”. Previous attempts to develop a reliable blood assay for p-tau181 have been challenging due to the very low concentrations in blood samples. Furthermore, initial unsuccessful efforts focused on applying established mid-region CSF p-tau181 immunoassays directly to blood. Recent evidence has shown that tau in blood and CSF might be processed differently, with mainly N-terminal forms of tau present in measurable quantities in blood. A few studies, each targeting different tau species, have described blood p-tau181 immunoassays showing encouraging results in few patient cohorts. However, some of these assays lack the analytical sensitivity for examining cognitively unimpaired individuals, some of whom might be in the preclinical phase of Alzheimer's disease. Moreover, it is unclear if previously described blood p-tau181 assays detect either Alzheimer-specific tau pathology similar to CSF p-tau181 or tau pathology that is common to all neurodegenerative diseases, characterised by the presence of pathological tau.
Added value of this study
In this study, we present a blood-based immunoassay measuring p-tau181 on a novel N-terminal form of tau that is distinct from the mid-region forms targeted by the established CSF assays. This assay was validated to be specific for the p-tau181 site, does not capture non-phosphorylated tau species, and shows good diagnostic performance for Alzheimer's disease in both plasma and serum. The blood p-tau181 assay identified Alzheimer's disease at the very early stages of disease and demonstrated high diagnostic accuracy, with stepwise increases across the Alzheimer's disease continuum. Similar to mid-region CSF p-tau181, our blood p-tau181 assay appeared to be specific to Alzheimer's disease, differentiating it from other neurodegenerative diseases with high accuracy. Additionally, blood p-tau181 predicted cognitive decline and hippocampal atrophy over a period of 1 year, making it suitable as an Alzheimer's disease progression marker. Furthermore, plasma p-tau181 performed better than the most well-known Alzheimer's disease risk factors (age, APOE ε4 genotype, or both) and other plasma biomarkers (total-tau, amyloid β1–42, amyloid β1–42 to amyloid β1–40 ratio, and total-tau to amyloid β1–42 ratio) in predicting Alzheimer's disease diagnosis, increased tau PET, and increased amyloid β PET.
Implications of all the available evidence
The blood p-tau181 assay described in this study could represent the first simple, practical, and scalable test for the diagnosis of Alzheimer's disease. This technology has applications for diagnosis and recruitment for disease-modifying trials. The blood p-tau181 assay has the potential to be incorporated into clinical practice as a rapid screening test to identify or rule out Alzheimer's disease pathophysiology and to guide therapy and clinical management of patients with suspected neurodegenerative disorders. To facilitate widespread implementation of the blood p-tau181 assay, full clinical standardisation, including establishment of reference materials and methods to harmonise readouts across clinical laboratories, will be required.